Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer

Bin Yuan, Long Cheng, Kshama Gupta, Huai Chin Chiang, Harshita B. Gupta, Gangadhara R Sareddy, Degeng Wang, Kate Lathrop, Richard M Elledge, Pei Wang, Stanton McHardy, Ratna K Vadlamudi, Tyler J Curiel, Yanfen Hu, Qinong Ye, Rong Li

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Unlike estrogen receptor α (ERα) that predominantly promotes hormone-dependent breast tumor growth, ERβ exhibits antitumor effects in a variety of cancer types. We recently identified a phosphotyrosine residue in ERβ, but not ERα, that dictates ERβ transcriptional activity and antitumor function. We show here that this ER isotype-specific phosphotyrosine switch is important for regulating ERβ activity in cell proliferation, migration, and invasion. At the mechanistic level, phosphorylated ERβ, which recruits transcriptional coactivator p300, is in turn targeted by p300 for ubiquitination and proteasome-dependent protein turnover. Furthermore, ERβ-specific agonists such as S-equol enhance ERβ phosphorylation, suggesting a crosstalk between ligand- and posttranslational modification-dependent ERβ activation. Inhibition of xenograft tumor growth by S-equol is associated with reduced tumor Ki-67 expression and elevated ERβ tyrosine phosphorylation. Taken together, our data support the notion that phosphotyrosine-dependent ERβ signaling is an attractive target for anticancer treatment.

Original languageEnglish (US)
Pages (from-to)42585-42597
Number of pages13
JournalOncotarget
Volume7
Issue number27
DOIs
StatePublished - Jul 5 2016

Fingerprint

Ubiquitination
Estrogen Receptors
Tyrosine
Phosphorylation
Breast Neoplasms
Phosphotyrosine
Equol
estrophilin
Neoplasms
Proteasome Endopeptidase Complex
Post Translational Protein Processing
Growth
Heterografts
Cell Movement
Estrogens
Cell Proliferation
Hormones
Ligands

Keywords

  • antitumor activity
  • ERβ
  • protein turnover
  • tyrosine phosphorylation
  • ubiquitination

ASJC Scopus subject areas

  • Oncology

Cite this

Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer. / Yuan, Bin; Cheng, Long; Gupta, Kshama; Chiang, Huai Chin; Gupta, Harshita B.; Sareddy, Gangadhara R; Wang, Degeng; Lathrop, Kate; Elledge, Richard M; Wang, Pei; McHardy, Stanton; Vadlamudi, Ratna K; Curiel, Tyler J; Hu, Yanfen; Ye, Qinong; Li, Rong.

In: Oncotarget, Vol. 7, No. 27, 05.07.2016, p. 42585-42597.

Research output: Contribution to journalArticle

Yuan, B, Cheng, L, Gupta, K, Chiang, HC, Gupta, HB, Sareddy, GR, Wang, D, Lathrop, K, Elledge, RM, Wang, P, McHardy, S, Vadlamudi, RK, Curiel, TJ, Hu, Y, Ye, Q & Li, R 2016, 'Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer', Oncotarget, vol. 7, no. 27, pp. 42585-42597. https://doi.org/10.18632/oncotarget.10018
Yuan, Bin ; Cheng, Long ; Gupta, Kshama ; Chiang, Huai Chin ; Gupta, Harshita B. ; Sareddy, Gangadhara R ; Wang, Degeng ; Lathrop, Kate ; Elledge, Richard M ; Wang, Pei ; McHardy, Stanton ; Vadlamudi, Ratna K ; Curiel, Tyler J ; Hu, Yanfen ; Ye, Qinong ; Li, Rong. / Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer. In: Oncotarget. 2016 ; Vol. 7, No. 27. pp. 42585-42597.
@article{fdb28cc0f11b4b5f89ac8a579e3a6e6d,
title = "Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer",
abstract = "Unlike estrogen receptor α (ERα) that predominantly promotes hormone-dependent breast tumor growth, ERβ exhibits antitumor effects in a variety of cancer types. We recently identified a phosphotyrosine residue in ERβ, but not ERα, that dictates ERβ transcriptional activity and antitumor function. We show here that this ER isotype-specific phosphotyrosine switch is important for regulating ERβ activity in cell proliferation, migration, and invasion. At the mechanistic level, phosphorylated ERβ, which recruits transcriptional coactivator p300, is in turn targeted by p300 for ubiquitination and proteasome-dependent protein turnover. Furthermore, ERβ-specific agonists such as S-equol enhance ERβ phosphorylation, suggesting a crosstalk between ligand- and posttranslational modification-dependent ERβ activation. Inhibition of xenograft tumor growth by S-equol is associated with reduced tumor Ki-67 expression and elevated ERβ tyrosine phosphorylation. Taken together, our data support the notion that phosphotyrosine-dependent ERβ signaling is an attractive target for anticancer treatment.",
keywords = "antitumor activity, ERβ, protein turnover, tyrosine phosphorylation, ubiquitination",
author = "Bin Yuan and Long Cheng and Kshama Gupta and Chiang, {Huai Chin} and Gupta, {Harshita B.} and Sareddy, {Gangadhara R} and Degeng Wang and Kate Lathrop and Elledge, {Richard M} and Pei Wang and Stanton McHardy and Vadlamudi, {Ratna K} and Curiel, {Tyler J} and Yanfen Hu and Qinong Ye and Rong Li",
year = "2016",
month = "7",
day = "5",
doi = "10.18632/oncotarget.10018",
language = "English (US)",
volume = "7",
pages = "42585--42597",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "27",

}

TY - JOUR

T1 - Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer

AU - Yuan, Bin

AU - Cheng, Long

AU - Gupta, Kshama

AU - Chiang, Huai Chin

AU - Gupta, Harshita B.

AU - Sareddy, Gangadhara R

AU - Wang, Degeng

AU - Lathrop, Kate

AU - Elledge, Richard M

AU - Wang, Pei

AU - McHardy, Stanton

AU - Vadlamudi, Ratna K

AU - Curiel, Tyler J

AU - Hu, Yanfen

AU - Ye, Qinong

AU - Li, Rong

PY - 2016/7/5

Y1 - 2016/7/5

N2 - Unlike estrogen receptor α (ERα) that predominantly promotes hormone-dependent breast tumor growth, ERβ exhibits antitumor effects in a variety of cancer types. We recently identified a phosphotyrosine residue in ERβ, but not ERα, that dictates ERβ transcriptional activity and antitumor function. We show here that this ER isotype-specific phosphotyrosine switch is important for regulating ERβ activity in cell proliferation, migration, and invasion. At the mechanistic level, phosphorylated ERβ, which recruits transcriptional coactivator p300, is in turn targeted by p300 for ubiquitination and proteasome-dependent protein turnover. Furthermore, ERβ-specific agonists such as S-equol enhance ERβ phosphorylation, suggesting a crosstalk between ligand- and posttranslational modification-dependent ERβ activation. Inhibition of xenograft tumor growth by S-equol is associated with reduced tumor Ki-67 expression and elevated ERβ tyrosine phosphorylation. Taken together, our data support the notion that phosphotyrosine-dependent ERβ signaling is an attractive target for anticancer treatment.

AB - Unlike estrogen receptor α (ERα) that predominantly promotes hormone-dependent breast tumor growth, ERβ exhibits antitumor effects in a variety of cancer types. We recently identified a phosphotyrosine residue in ERβ, but not ERα, that dictates ERβ transcriptional activity and antitumor function. We show here that this ER isotype-specific phosphotyrosine switch is important for regulating ERβ activity in cell proliferation, migration, and invasion. At the mechanistic level, phosphorylated ERβ, which recruits transcriptional coactivator p300, is in turn targeted by p300 for ubiquitination and proteasome-dependent protein turnover. Furthermore, ERβ-specific agonists such as S-equol enhance ERβ phosphorylation, suggesting a crosstalk between ligand- and posttranslational modification-dependent ERβ activation. Inhibition of xenograft tumor growth by S-equol is associated with reduced tumor Ki-67 expression and elevated ERβ tyrosine phosphorylation. Taken together, our data support the notion that phosphotyrosine-dependent ERβ signaling is an attractive target for anticancer treatment.

KW - antitumor activity

KW - ERβ

KW - protein turnover

KW - tyrosine phosphorylation

KW - ubiquitination

UR - http://www.scopus.com/inward/record.url?scp=85025830426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025830426&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10018

DO - 10.18632/oncotarget.10018

M3 - Article

VL - 7

SP - 42585

EP - 42597

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 27

ER -